November 2008- Volume 4, Issue 11

In this Issue

Research & Development

Better late than never

Better late than never

ARCA biopharma, Nuvelo merger creates late-stage cardiovascular biotech

A partner's partnership

A partner's partnership

Ligand's acquisition of Pharmacopeia to focus on Big Pharma partnerships

Easier way to make stem cells

Easier way to make stem cells

Harvard researchers use chemicals in place of two cancer genes in reprogramming process

Late-stage letdown

Late-stage letdown

Cell Genesys axes 75 percent of staff after cancelling VITAL-1 Phase III trials

Cooperating for a worthy cause

Cooperating for a worthy cause

Eli Lilly, Merck and IDRI tackle global threat of TB

Genomics & Proteomics

Slashing genome prices

Slashing genome prices

Complete Genomics promises $5,000 human whole-genome sequencing by next year

Giving RNAi some lip service

Giving RNAi some lip service

RXi Pharma obtains exclusive worldwide license to technology for the oral RNAi delivery

Getting in touch with our inner germs

Getting in touch with our inner germs

NIH kicks off the Human Microbiome Project with first awards

Automation & Instrumentation

A perfect deal from A to Z

A perfect deal from A to Z

Advalytix to private-label ZyGEM's temperature-controlled extraction technology

Speeding up ADME

Speeding up ADME

BD Biosciences, BioTrove to provide a solution from sample prep to data analysis

Radiolabeling for ADME

Radiolabeling for ADME

PerkinElmer launches GMP radiolabeling services

Invitrogen hepatocytes pair with Qualyst’s B-Clear

Invitrogen hepatocytes pair with Qualyst’s B-Clear

In a move that should markedly enhance the market opportunities for Qualyst’s B-Clear hepatocyte research kits and contract services, the company has agreed with Invitrogen to offer hepatocyte screening services and research products through the latter’s wholly-owned subsidiary, CellzDirect.

Feature

Lighting up in vitro and in vivo work

Lighting up in vitro and in vivo work

Imaging technologies, particularly luminescent ones, are increasingly important to discovery/development

Global News

Focus on emerging markets

Focus on emerging markets

GSK snags Egyptian mature products business of Bristol-Myers Squibb for $210 million

Coming in from the cold

Coming in from the cold

Lipoxen, Cambridge Biostability work to develop improved vaccines that are stable at ambient temperatures

Pfizer, UCB announce joint venture

Pfizer, UCB announce joint venture

New company Cyclofluidic aims to accelerate drug discovery via automating flow chemistry, flow biology

Theratechnologies, EMD Serono in HIV tesamorelin licensing deal

Theratechnologies, EMD Serono in HIV tesamorelin licensing deal

Theratechnologies Inc. and EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced the companies entered a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

Informatics

Making massive models

Making massive models

Biogen Idec to process inflammatory disease data using Gene Network Sciences' REFS software

Bringing down Big Pharma's fortress

Bringing down Big Pharma's fortress

SIMDAT Project ends with successful virtual outsourcing project at GSK

Early warning system

Early warning system

CSS Informatics, DrugLogic integrate safety data technologies to allow early detection of adverse trial events

In-depth in silico discovery

In-depth in silico discovery

Life Biosystems, Temis solution offers analysis of large-scale bibliographic information

Gunning for genomics

Gunning for genomics

Integromics, Tibco roll out genomics data analysis solution

Editor's Focus

Economic meltdown and where the money is

Economic meltdown and where the money is

It’s pretty hard to be the editor of a business publication and not address the recent world-wide economic meltdown. What’s to make of this mess, and what are the potential impacts on the biotech and pharmaceutical industry?

Commentary

Now what do we do? Challenges abound in life sciences for new graduates and experienced alike

Now what do we do? Challenges abound in life sciences for new graduates and experienced alike

Twenty years ago, life in Big Pharma was genteel and secure. Today, it is neither. There are always good career opportunities for the best, and the only way to be the best is to get to work and not wait for miracles.

A solid team in the life sciences

A solid team in the life sciences

Just as our editorial staff delivers the news to our readers, our sales staff delivers integrated marketing opportunities to the advertising community. DDN is very fortunate that in our fourth year, we have a veteran sales team, all of whom have deep and significant experience in life science publishing, to help our advertisers design their own customized integrated marketing programs.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue